Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

P. Balsas, A. Esteve-Arenys, J. Roldán, L. Jiménez, V. Rodríguez, J. G. Valero, A. Chamorro-Jorganes, R. Puig De La Bellacasa, J. Teixidó, A. Matas-Céspedes, A. Moros, A. Martínez, E. Campo, A. Sáez-Borderías, J. I. Borrell, P. Pérez-Galán, D. Colomer, G. Roué

Research output: Indexed journal article Articlepeer-review

10 Citations (Scopus)

Abstract

Background: Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Bruton’s kinase (Btk) and spleen tyrosine kinase (Syk) inhibitors, a small fraction of patients tend to develop progressive disease after initial response to these agents. Methods: We evaluated the antitumor activity of IQS019, a new BCR kinase inhibitor with increased affinity for Btk, Syk, and Lck/Yes novel tyrosine kinase (Lyn), in a set of 34 B lymphoid cell lines and primary cultures, including samples with acquired resistance to the first-in-class Btk inhibitor ibrutinib. Safety and efficacy of the compound were then evaluated in two xenograft mouse models of B cell lymphoma. Results: IQS019 simultaneously engaged a rapid and dose-dependent de-phosphorylation of both constitutive and IgM-activated Syk, Lyn, and Btk, leading to impaired cell proliferation, reduced CXCL12-dependent cell migration, and induction of caspase-dependent apoptosis. Accordingly, B cell lymphoma-bearing mice receiving IQS019 presented a reduced tumor outgrowth characterized by a decreased mitotic index and a lower infiltration of malignant cells in the spleen, in tight correlation with downregulation of phospho-Syk, phospho-Lyn, and phospho-Btk. More interestingly, IQS019 showed improved efficacy in vitro and in vivo when compared to the first-in-class Btk inhibitor ibrutinib, and was active in cells with acquired resistance to this latest. Conclusions: These results define IQS019 as a potential drug candidate for a variety of B lymphoid neoplasms, including cases with acquired resistance to current BCR-targeting therapies.

Original languageEnglish
Article number80
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
Publication statusPublished - 31 Mar 2017

Keywords

  • B-NHL
  • Btk
  • Cell migration
  • Lyn
  • Mouse model
  • Syk

Fingerprint

Dive into the research topics of 'Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this